{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:04Z","timestamp":1786987024623,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.clgc.2023.03.017","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T11:36:55Z","timestamp":1680521815000},"page":"e343-e351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib\u00a0+\u00a0Checkpoint Inhibitor"],"prefix":"10.1016","volume":"21","author":[{"given":"Yousef","family":"Zakharia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3110-6775","authenticated-orcid":false,"given":"Lynn","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2896-7873","authenticated-orcid":false,"given":"Shawn","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjana","family":"Sundaresan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-6687","authenticated-orcid":false,"given":"Mei S.","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Thomaidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2023.03.017_bib0001","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","volume":"7","author":"Chow","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2023.03.017_bib0002","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: kidney and renal pelvis cancer. Bethesda, MD. 2021. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html (Accessed: October 21, 2021)."},{"key":"10.1016\/j.clgc.2023.03.017_bib0003","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.humpath.2018.01.010","article-title":"Trends in reporting histological subtyping of renal cell carcinoma: association with cancer center type","volume":"74","author":"Gansler","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clgc.2023.03.017_bib0004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.03.017_bib0005","doi-asserted-by":"crossref","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.clgc.2023.03.017_bib0006","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2023.03.017_bib0007","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.clgc.2018.10.002","article-title":"Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study","volume":"17","author":"Saad","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2023.03.017_bib0008","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1080\/07357900802709167","article-title":"CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value","volume":"27","author":"Liang","year":"2009","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clgc.2023.03.017_bib0009","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/jcla.10074","article-title":"Expression of vascular endothelial growth factor in renal cell carcinoma is correlated with cancer advancement","volume":"17","author":"Yang","year":"2003","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.clgc.2023.03.017_bib0010","first-page":"1","article-title":"Current approaches to the treatment of advanced or metastatic renal cell carcinoma","volume":"40","author":"Tenold","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clgc.2023.03.017_bib0011","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s40425-019-0813-8","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)","volume":"7","author":"Rini","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.clgc.2023.03.017_bib0012","series-title":"KEYTRUDA (pembrolizumab) Prescribing Information","year":"2021"},{"key":"10.1016\/j.clgc.2023.03.017_bib0013","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.03.017_bib0014","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2023.03.017_bib0015","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2021.39.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426","volume":"39","author":"Rini","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.03.017_bib0016","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.03.017_bib0017","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.03.017_bib0018","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1200\/JCO.2021.39.6_suppl.301","article-title":"Efficacy and safety of avelumab plus axitinib (A\u00a0+\u00a0Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101","volume":"39","author":"Tomita","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.03.017_bib0019","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1200\/JCO.2021.39.15_suppl.4574","article-title":"Efficacy of avelumab\u00a0+\u00a0axitinib (A\u00a0+\u00a0Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101","volume":"39","author":"Haanen","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.03.017_bib0020","series-title":"BAVENCIO (avelumab) Prescribing Information","year":"2020"},{"key":"10.1016\/j.clgc.2023.03.017_bib0021","series-title":"INLYTA (axitinib) Prescribing Information","year":"2020"},{"key":"10.1016\/j.clgc.2023.03.017_bib0022","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cac2.12183","article-title":"Improving antitumor immunity using antiangiogenic agents: mechanistic insights, current progress, and clinical challenges","volume":"41","author":"Li","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.clgc.2023.03.017_bib0023","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1080\/14712598.2021.1890713","article-title":"Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma","volume":"21","author":"St\u00fchler","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.clgc.2023.03.017_bib0024","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3389\/fphar.2019.01173","article-title":"Adverse events of concurrent immune checkpoint inhibitors and antiangiogenic agents: a systematic review","volume":"10","author":"Gao","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clgc.2023.03.017_bib0025","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41416-020-0949-9","article-title":"Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events","volume":"123","author":"Gr\u00fcnwald","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2023.03.017_bib0026","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"key":"10.1016\/j.clgc.2023.03.017_bib0027","unstructured":"US Food and Drug Administration. What is a serious adverse event? 2016. Available at: https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event (Accessed: January 31, 2022)."},{"key":"10.1016\/j.clgc.2023.03.017_bib0028","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejcsup.2013.07.016","article-title":"Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors","volume":"11","author":"Schmidinger","year":"2013","journal-title":"EJC Suppl"},{"key":"10.1016\/j.clgc.2023.03.017_bib0029","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2023.03.017_bib0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/11591240-000000000-00000","article-title":"Axitinib for the management of metastatic renal cell carcinoma","volume":"11","author":"Escudier","year":"2011","journal-title":"Drugs R D"},{"key":"10.1016\/j.clgc.2023.03.017_bib0031","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clgc.2016.05.008","article-title":"Axitinib versus sorafenib in first-line metastatic renal cell carcinoma: overall survival from a randomized phase III trial","volume":"15","author":"Hutson","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2023.03.017_bib0032","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12032-018-1231-3","article-title":"Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis","volume":"36","author":"Konishi","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.clgc.2023.03.017_bib0033","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2017.04.015","article-title":"Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre","volume":"79","author":"Matias","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2023.03.017_bib0034","doi-asserted-by":"crossref","first-page":"540-7.e1-7","DOI":"10.1016\/j.clgc.2015.07.001","article-title":"Long-term safety with axitinib in previously treated patients with metastatic renal cell carcinoma","volume":"13","author":"Rini","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2023.03.017_bib0035","doi-asserted-by":"crossref","first-page":"15_suppl","DOI":"10.1200\/JCO.2021.39.15_suppl.e16536","article-title":"Tolerability of axitinib in advanced renal cell carcinoma: a meta-analysis","volume":"39","author":"Chaudhry","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.03.017_bib0036","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1016\/j.clgc.2021.03.019","article-title":"Time to resolution of axitinib-related adverse events after treatment interruption in patients with advanced renal cell carcinoma","volume":"19","author":"Rini","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2023.03.017_bib0037","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1200\/JCO.2021.39.6_suppl.294","article-title":"Axitinib and avelumab (AA) as first-line treatment of metastatic renal cell carcinoma (mRCC): a real-world outcome review in the Northwest of England, United Kingdom","volume":"39","author":"Allison","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:38:15Z","timestamp":1761565095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323000861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1558767323000861"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.03.017","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib\u00a0+\u00a0Checkpoint Inhibitor","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}